+44 7723 059341
CMC is the one risk a sponsor controls, yet it is often reviewed only after a setback. Z2 provides independent scientific and technical assessment of cell line, upstream and associated CMC strategies – supporting development programmes, regulatory readiness, investment decisions and technology evaluation.
74%
of FDA rejection letters issued 2020–2024 cited quality or manufacturing (CMC) deficiencies1
65%
of rejection letters for later-approved drugs cited manufacturing-facility problems2
1.3 years
median delay from rejection letter to eventual approval2
CMC planning & regulatory review
- A CMC plan, budget and risk register set up front
- Independent review of CLD and upstream programmes: rationale, data maturity, process understanding and scalability
- Review and contribution to IND/BLA documentation and supporting technical content
- Experience with regulatory submissions and agency interactions including FDA and MHRA
- Documentation review for scientific consistency, traceability and regulatory readiness
Technical due diligence
Independent, evidence-based assessment for biotechnology companies, investors, funders and strategic partners – evaluating technology maturity, proof-of-concept evidence, development strategy, scalability, CMC readiness, technical risks and key development gaps to support investment, partnership, acquisition or programme-progression decisions.
- Technology maturity: is the science real, and how far has it been taken?
- Scalability: does the process survive manufacturing scale?
- Development risk: capability gaps and unproven assumptions
- CMC readiness, including CDMO location under the BIOSECURE Act
Where rushed timelines break
Diligence reads CMC summaries, not raw data.
Where Z2 helps
A data-room review of clone, process and CDMO, with a red-flag report.
Investment, grant & fundraising readiness
Strong proof-of-concept data can sit alongside a process that cannot scale – a mismatch that is usually invisible to non-technical funders. UK biotech venture deals fell from 111 in 2024 to 58 in 2025, so every proposition has to stand up to scrutiny.3
−48%
fall in UK biotech venture deals in 2025 (111 → 58)3
£1.8B
UK biotech VC in 2025, down 13.2% from £2.1B in 2024 (£1.3B in 2023)3
£2.6B
UK biotech VC in H1 2026 alone, led by Isomorphic Labs4
30%
of European biotech venture capital went to UK companies in 20253
- Assess: technology maturity, bioprocess strategy, scalability, evidence quality and technical risk
- Articulate: scientific input to grant applications, funding proposals, investor presentations and technical narratives
- Assure: independent CMC-focused due diligence for investors and partners
Where rushed timelines break
Budgets with no line for technology transfer or rework.5
Where Z2 helps
A CMC plan, budget and risk register that reviewers can check line by line.
Sources
- Pharmaceutical Technology. CMC and analytical gaps in CRLs: why they persist despite FDA guidance, July 2026.
- Deficiencies Delaying Prescription Drug Approvals by the US FDA, 2020–2024: cross-sectional analysis of 43 novel therapeutics with CRLs. PubMed 41670800, 2026.
- BioIndustry Association. UK biotech financing 2025, Jan 2026.
- BIA / Biotech Finance. UK biotech financing Q2 2026.
- BioPharm International. Current challenges with cell culture scale-up for biologics production.
